SLC5A2 and type 2 diabetes mellitus: Demographic data, clinical characteristics, and prescription of drugs at the baseline and endpoint in patients with type 2 diabetes treated with or without sodium glucose cotransporter-2 inhibitor and at baseline in control subjects.